The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

"Medidata is at the forefront of a critical shift in the life sciences sector," said Anthony Costello, CEO, Medidata. "By harnessing AI-powered solutions and partnering with visionaries, we aren't ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but missing out on overall survival.

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. | Merck & Co. and Eisai have to deal with ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...